Senti Biosciences Faces Financial Challenges Amid Strategic Focus - TipRanks

SNTI Stock  USD 4.36  0.06  1.36%   
Under 55% of Senti Biosciences' traders are presently thinking to get in. The analysis of the overall investor sentiment regarding Senti Biosciences suggests that some traders are interested. Senti Biosciences' investing sentiment shows overall attitude of investors towards Senti Biosciences.
  
Senti Biosciences Faces Financial Challenges Amid Strategic Focus TipRanks

Read at news.google.com
Google News at Macroaxis
  

Senti Biosciences Fundamental Analysis

We analyze Senti Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Senti Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Senti Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Senti Biosciences is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Senti Biosciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Senti Biosciences stock to make a market-neutral strategy. Peer analysis of Senti Biosciences could also be used in its relative valuation, which is a method of valuing Senti Biosciences by comparing valuation metrics with similar companies.

Peers

Senti Biosciences Related Equities

QNRXQuoin Pharmaceuticals   13.79   
0%
100.0%
CVKDCadrenal Therapeutics,   3.89   
0%
28.0%
MNPRMonopar Therapeutics   3.39   
0%
24.0%
XLOXilio Development   1.43   
0%
10.0%
SABSSAB Biotherapeutics   0.92   
0%
6.0%
MLYSMineralys Therapeutics,   0.29   
0%
2.0%
FENCFennec Pharmaceuticals   0.76   
5.0%
0%
CNTBConnect Biopharma   1.02   
7.0%
0%
LIPOLipella Pharmaceuticals   1.48   
10.0%
0%
TYRATyra Biosciences   1.70   
12.0%
0%
RAPTRAPT Therapeutics   2.56   
18.0%
0%
FHTXFoghorn Therapeutics   3.46   
25.0%
0%
CINGCingulate   4.01   
29.0%
0%

Complementary Tools for Senti Stock analysis

When running Senti Biosciences' price analysis, check to measure Senti Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senti Biosciences is operating at the current time. Most of Senti Biosciences' value examination focuses on studying past and present price action to predict the probability of Senti Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senti Biosciences' price. Additionally, you may evaluate how the addition of Senti Biosciences to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals